Answers are grounded in this paper and cite their sources.
Supply chain disruptions pose significant challenges for pharmaceutical supply chains (PSCs) leading to shortages of essential medicines and compromising patient care. Ensuring resilience in PSCs therefore requires an improved understanding of how supply chain vulnerabilities can be addressed through resilience capabilities. While supply chain resilience research has identified numerous vulnerabilities and resilience capabilities, limited attention has been paid to how these elements are interconnected within pharmaceutical supply chains and how managers can prioritize resilience-building actions under different vulnerability conditions. This study addresses this gap by developing and empirically grounding a PSC resilience framework that explicitly links supply chain vulnerabilities and resilience capabilities. A sequential mixed-methods approach was employed, combining an extensive literature review, semi-structured interviews with senior pharmaceutical supply chain experts, and a structured expert survey. The resulting vulnerability-capability relationships were subsequently operationalized through a Technique for Order Preference by Similarity to Ideal Solution decision-support model to support capability prioritization under alternative vulnerability scenarios. The findings identify five key vulnerability dimensions, namely supply chain structure, product and production complexity, law and regulatory issues, environmental factors, and intentional attacks, as well as ten resilience capabilities. The results demonstrate that resilience capability priorities vary substantially across vulnerability contexts. Preparedness, flexibility and redundancy, proactive inventory management, and experienced personnel emerge as particularly important capabilities, although their relative importance depends on the underlying vulnerability profile. This study contributes to the supply chain resilience literature by advancing a pharmaceutical supply chain resilience framework that explicitly links vulnerabilities and resilience capabilities, thereby providing a more context-sensitive understanding of resilience in highly regulated industries. Furthermore, it introduces a decision-support approach that enables scenario-specific capability prioritization and supports resilience-oriented decision-making in pharmaceutical supply chains.
No takes yet. Share an insight, caveat, or question.
Eberhardt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: